C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab
Eduard Roussel, Lisa Kinget, Annelies Verbiest, Philip R. Debruyne, Marcella Baldewijns, Hendrik Van Poppel, Maarten Albersen, Benoit Beuselinck
Topics & Concepts
NivolumabRenal cell carcinomaMedicineNeutrophil to lymphocyte ratioLymphocyteOncologyInternal medicineCancer researchImmunologyImmunotherapyCancerRenal cell carcinoma treatmentInflammatory Biomarkers in Disease PrognosisCancer Immunotherapy and Biomarkers